ROIV: FDA approval, best-in-class PH-ILD data, and robust pipeline drive strong outlook

Roivant Sciences secured FDA approval for brepocitinib, demonstrated leading clinical data for mosliciguat in PH-ILD, and showed strong efficacy for IMVT-1402 in RA, with multiple late-stage readouts and product launches expected next year.

This Wire brief sits within Fusion42's coverage of Biotech.